BMRN Q3 deep dive: pipeline expansion and order timing weigh on guidance

What happened

BioMarin Pharmaceutical reported third-quarter 2026 revenue of $1.02 billion, up 32% year over year and in line with analyst estimates, while adjusted profit was $0.23 per share. It lowered full-year revenue guidance to $3.85 billion at the midpoint and adjusted profit guidance to $2.95 per share.

Confirmed

Global impact / market context

Revenue growth and stronger-than-expected quarterly adjusted profit point to solid recent sales and cost performance, but lower annual forecasts signal a weaker expected finish. If the forecast reduction reflects delayed orders or expansion costs, it could affect future revenue timing and spending decisions; the supplied article does not specify the cause.

Analyst inference

The results present a mixed picture: quarterly revenue matched expectations and adjusted profit exceeded them, yet full-year revenue guidance was 1.8% below analysts’ estimates. The company also reduced its revenue midpoint from $3.9 billion to $3.85 billion and cut adjusted profit guidance.

Confirmed

What to watch

1. Check upcoming company updates for whether sales of Galafold and Pombiliti plus Opfolda continue to support revenue growth; the article identifies these therapies as demand drivers. Analyst inference
2. Watch for further detail on the lower annual revenue and adjusted profit forecasts, including whether management links them to order timing, pipeline expansion, or other factors. Analyst inference
3. Compare later reported full-year revenue and adjusted profit with the revised guidance of $3.85 billion and $2.95 per share, respectively, to assess delivery. Analyst inference

Evidence

• stockstory.org